- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04059133
The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder
Study Overview
Status
Conditions
Detailed Description
Clinical application of low intensity extracorporeal low energy shock wave therapy (LiESWT) (2000 to 3000 impulses in 0.20-0.25 millijoule/mm2 (mJ/mm2)) initiated wound healing, promoted angiogenesis, reduced the level of oxidative stress, induced the releasing of VEGF, stimulated proliferation and differentiation of stem cells, and resulted in the effect of anti-inflammatory and tissue regeneration. Generally, LiESWT was used clinically to improve tissue regeneration at tendon-bone junctions, ischemic cardiovascular disorders, skin wound healing, chronic injuries of soft tissues and erectile dysfunction.
LiESWT has also been shown to increase vascular endothelial growth factor (VEGF) expression in ischemic tissues in vivo and to promote angiogenesis and functional recovery in models of chronic myocardial ischemia, myocardial infarction, and peripheral artery disease. Importantly, the advantages of LiESWT include therapies without medication or surgery, outpatient therapies, short treatment sessions, no anesthesia required, and non-invasive therapy.
The hypothesis of the present study is LiESWT can decrease inflammatory disorders, increase pelvic floor blood supply, enhanced bladder stem cell activation, Using LiESWT can decrease bladder overactivity, eliminate urinary incontinence and improve stress urinary incontinence (SUI) and overactive bladder (OAB) symptoms. Therefore improve quality of life and improve social activity.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 807
- Recruiting
- Kaohsiung Medical University Hospital
-
Contact:
- Yung-Shun Juan, MD., PhD
- Phone Number: 6361 88673121101
- Email: juanuro@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women patients within 20~75 years old;
- OAB symptoms for ≥ 3 months;
- Frequency of micturition ≥ 8 times daytime as well as 2 times nighttime, and ≥ 2 episodes of urgency per week;
- Patients have a ≥ 3 month history of experiencing Stress Urinary Incontinence (SUI) per week (self reported);
- Patients with OAB symptoms including urgency or/and urgency incontinence, urinary frequency and nocturia in the previous 3 months without medical treatments: antimuscarinic or ß3 agonist therapy;
- Patients can understand, obey order and finish the questionnaires;
- Patients would like to sign the informed consent;
- Signature of informed consent form.
Exclusion Criteria:
- Urinary tract infection (UTI) at screening and recurrent UTI defined as ≥ 3 UTIs in the previous 12 months;
- Patients who have other disease: diabetes mellitus, spinal cord injury, stoke history, brain disease and neurogenic disease which can cause OAB;
- Chronic urologic inflammatory condition (Interstitial cystitis, urethral syndrome, painful bladder syndrome);
- Bladder stone;
- History of carcinoma of the urinary tract;
- Lower urinary tract surgery in the last 6 months;
- Patients who have operation, wound or infection around perineum;
- Patients who have catheterization due to poor voiding function of urine;
- Patients who have severe cardiovascular disease;
- Patients who have severe coagulopathy or liver failure or renal failure;
- Patients who have underlying urologic cancer;
- Subjects with gross hematuria;
- Significant bladder outflow obstruction;
- Previous pelvic radiation therapy or previous, current malignant disease of the pelvic organs or having received intravesical injection or electrostimulation in the past 12 months;
- Drug or nondrug treatments of OAB (in the previous 14 days), Concomitant medications that affect detrusor activity;
- Subjects with history of kidneys stones;
- Treatable condition that could cause urinary incontinence or urgency;
- Neurological impairment or psychiatric disorder preventing appropriate understanding of consent and ability to comply with site personnel instructions;
- History of drug or alcohol abuse within the last 12 months;
- Within 1 month before entering the test and receive low-energy in vitro shock wave treatment process using antibiotics or phosphodiesterase inhibitors type 5 (PDE5i);
- There are chronic pelvic pains caused by the merger of other diseases or injuries;
- Urinary incontinence need to install the catheter;
- Severe cardiopulmonary disease or diabetes is obviously poor control;
- Obvious coagulation dysfunction or liver and kidney dysfunction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LiESWT arm
|
Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
|
SHAM_COMPARATOR: Sham arm
|
Sham treatment (shock wave probe w/o energy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pad Weight Difference
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
The pad test quantifies in grams urinary loss through the absorbent weighing as a measure of stress urinary incontinence.
|
Data will be analyzed at study completion at approximately 3 years.
|
Overactive bladder symptoms scores (OABSS)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
Change in OABSS scores during LiESWT treatment and follow-up period.
|
Data will be analyzed at study completion at approximately 3 years.
|
International Consultation on Incontinence Questionnaire -- Short Form (ICIQ-SF)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
Change in ICIQ-SF scores during LiESWT treatment and follow-up period.
|
Data will be analyzed at study completion at approximately 3 years.
|
Urogenital distress inventory (UDI-6)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
Change in UDI-6 scores during LiESWT treatment and follow-up period.
|
Data will be analyzed at study completion at approximately 3 years.
|
Incontinence impact questionnaire -7 (IIQ-7)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
Change in IIQ-7 scores during LiESWT treatment and follow-up period.
|
Data will be analyzed at study completion at approximately 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum flow rate(Qmax=cc/s)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
The maximum flow rate is the most important uroflowmetry index to diagnose bladder outlet obstruction or bladder contractility.
|
Data will be analyzed at study completion at approximately 3 years.
|
Uroflow
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
Uroflow curve pattern: There are 5 uroflow curve patterns, bell-shaped, tower-shaped, interrupted-shaped, staccato-shaped and plateau shaped by uroflowmetry.
The shape is determined by detrusor contractility and influenced by abdominal straining, coordination with the bladder outlet musculature and any distal anatomic obstruction.
|
Data will be analyzed at study completion at approximately 3 years.
|
postvoid residual urine volume (PVR)
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
PVR (cc): ultrasonographic bladder scan machines calculates bladder volume.
PVR measurements in neurologically intact children are highly variable.
PVR must be obtained immediately after voiding(<5min).
|
Data will be analyzed at study completion at approximately 3 years.
|
3-day micturition diary
Time Frame: Data will be analyzed at study completion at approximately 3 years.
|
The mean number of Intake (ml), output (ml), average urine volume (ml), functional bladder capacity (ml), urinary frequency (times/24hrs), urgency (times), and nocturia (times) per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
|
Data will be analyzed at study completion at approximately 3 years.
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KMUHIRB-F(II)-20180010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm
-
Khadra Mohamed AliCairo UniversityEnrolling by invitationStress Incontinence, MaleEgypt
-
University of Southern DenmarkCompletedProstatic Diseases | Erectile Dysfunction | Post-Op ComplicationDenmark
-
University of AlbertaRecruiting
-
University of Roma La SapienzaCompletedMobility Limitation | Pain Syndrome | Gluteal Tendinitis | Trochanteric Syndrome | Bursitis HipItaly
-
University of Roma La SapienzaCompleted